title: Anti-diabetic effects of pentamethylquercetin in neonatally streptozotocin-induced diabetic rats.
abstract: Pentamethylquercetin (PMQ), a methylated quercetin derivative, was screened for anti-diabetic effects in neonatally streptozotocin (STZ)-induced diabetic rats (n-STZ diabetic rats). Streptozotocin (90 mg/kg) was administered intraperitoneally to 2-day-old male pups to induce diabetes. PMQ was administered at doses of 2.5, 5, 10 and 20mg/kg/day orally when the rats were 6 weeks old and continued for 10 consecutive weeks. Body weights were followed. Fasting and fed glucose, triglyceride and insulin levels were monitored periodically at the 6th and 10th week after PMQ treatment. At the end of the study, oral glucose tolerance test was performed, and kidney and liver function parameters were assayed. It was found that PMQ intervention dose-dependently reduced postprandial glucose and triglyceride levels, prevented the onset of overt diabetes, ameliorated polydipsia symptom induced by diabetes, attenuated glucose intolerance, enhanced insulin sensitivity indices and decreased endogenous creatinine clearance rate, urinary albumin excretion rate and blood alanine aminotransferase levels of n-STZ diabetic rats in comparison to their diabetic counterparts. The results from the present study thus suggest that PMQ exhibits great potential as an antidiabetic agent by improving hyperglycemia and reducing the incidence of peripheral complications.
authors: Department of Pharmacology, Basic Medical School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
authors: Yan
authors: Y
authors: Wang
authors: Xin
authors: X
authors: Xin
authors: Zhendong
authors: Z
authors: Jin
authors: Yan
authors: Y
authors: Hu
authors: Xianhui
authors: X
authors: Li
authors: Jianzhao
authors: J
authors: Wu
authors: Manwen
authors: M
authors: Jin
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D011794:Quercetin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000097:blood
chemical_list: C548139:3,3',4',5,7-pentamethylquercetin; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D014280:Triglycerides; D011794:Quercetin